1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legal & IP

Medtech And US DoJ: A Snapshot Of 2016 Pay-Outs And Pleas

 
• By Elizabeth Orr

The US Department of Justice has announced resolution of 14 device-related investigations in 2016, including settlements, guilty pleas and a few executive convictions. The largest settlement this year, with Olympus Corp., accounted for almost three-quarters of the $825.5m total value of medtech fines in 2016.

Gavel_1200x675

Federal investigations into device companies and health-care provide use of devices has become a fact of life for industry. 2016 was no exception. There have been 14 device-related investigations resolved with the US Department of Justice this year, through Dec. 13.

The largest device-related settlement announced by DoJ in 2016 was with Olympus Corp. of the Americas. The maker of endoscopes and other devices settled for $646m in civil and criminal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Policy & Regulation

Commission’s Flora Giorgio Says Simplification And Safety Are Key In Evolving EU Regs

 
• By Amanda Maxwell

Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.

Pathogen Sharing System Part Of Global Pandemic Agreement

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.

FDA Halts Acceptance Of Chinese Lab Data Due To Accuracy Issues

 
• By Elizabeth Orr

The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.